StockData
Petros Pharmaceuticals, Inc. logo

Petros Pharmaceuticals, Inc. (PTPI) stock

PTPIOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026Score 5/30
$0.00+0.00 (+5.56%)

Close on Oct 19, 2026Market cap $135.07KP/E –Yield –

Petros Pharmaceuticals operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Petros Pharmaceuticals's operating income for the twelve months ending Jun 30, 2026 was -$3.40M. For fiscal 2025 it was -$4.64M. The highest annual figure on record is -$4.63M in fiscal 2024.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$4.64M–
FY2024Dec 31, 2024-$4.63M–
FY2023Dec 31, 2023-$13.62M–
FY2022Dec 31, 2022-$19.92M–
FY2021Dec 31, 2021-$18.05M–
FY2020Dec 31, 2020-$17.28M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$988.50K–
Q1 FY2026Mar 31, 2026-$1.03M–
Q4 FY2025Dec 31, 2025-$391.49K–
Q3 FY2025Sep 30, 2025-$990.74K–
Q2 FY2025Jun 30, 2025-$1.80M–
Q1 FY2025Mar 31, 2025-$1.46M–
Q4 FY2024Dec 31, 2024-$577.55K–
Q3 FY2024Sep 30, 2024-$1.20M–
Q2 FY2024Jun 30, 2024-$1.35M–
Q1 FY2024Mar 31, 2024-$1.50M–
Q4 FY2023Dec 31, 2023-$5.04M–
Q3 FY2023Sep 30, 2023-$4.81M–
Q2 FY2023Jun 30, 2023-$2.46M–
Q1 FY2023Mar 31, 2023-$1.31M–
Q4 FY2022Dec 31, 2022-$4.10M–
Q3 FY2022Sep 30, 2022-$13.67M–
Q2 FY2022Jun 30, 2022-$1.66M–
Q1 FY2022Mar 31, 2022-$481.20K–
Q2 FY2021Jun 30, 2021-$4.28M–
Q1 FY2021Mar 31, 2021-$2.20M–
Q4 FY2020Dec 31, 2020-$4.32M–
Q3 FY2020Sep 30, 2020-$2.34M–
Q2 FY2020Jun 30, 2020-$5.02M–
Q1 FY2020Mar 31, 2020-$5.61M–

More Petros Pharmaceuticals figures

See a number that looks wrong?